OncoMatch/Clinical Trials/NCT05933239
Macrophage Imaging Using Ga-MMR-VHH2 in Lung Cancer Patients
Is NCT05933239 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies 68GaNOTA-Anti-MMR-VHH2 for non-small cell lung cancer.
Treatment: 68GaNOTA-Anti-MMR-VHH2 — Phase II study to evaluate the clinical potential of 68GaNOTA-anti-MMR-VHH2 for in vivo imaging of Macrophage Mannose Receptor (MMR)-expressing Macrophages by means of Positron Emission Tomography (PET) in patients with non-small cell lung cancer (NSCLC) planned for surgical resection.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05933239 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages